

References

L-28

1. Gradilone A, Naso G, Raimondi C, et al. Circulating tumor cells (CTCs) in metastatic breast cancer (MBC). *Annals of Oncology*. 2011; 22(1):86-92.
2. Wang S, Owens GE, Tseng HR. Nano "Fly Paper" technology for the capture of circulating tumor cells. *Methods Mol Biol*. 2011; 726:141-150.
3. Yu M, Stott S, Toner M, Maheswaran S, Haver D. Circulating tumor cells: approaches to isolation and characterization. *JCB Home*. 2011; 192(3):373.
4. Chang X, Ye X, Dong L, et al. Human Epididymis Protein 4 (HE4) as a serum tumor biomarker in patients with ovarian carcinoma. *Int Journal of Gynecology Cancer*. 2011.
5. Wang F, Chen L, Ding W, et al. Serum APRIL, a potential tumor marker in pancreatic cancer. *Clin Chem Lab Med*. 2011.
6. Kato K, Taniguchi M, Kawakami T, et al. Gastric cancer with a very high serum Ca 19-9 level. *Case Rep Gastroenterology*. 2011;5(10):258-261.
7. Dragomir A, Moldoveanu E, Mihăltan F. Update regarding the role of biomarkers in early diagnosis of non-small cell bronchopulmonary cancer. *Pneumologia*. 2011; 60(1):7, 9-13.
8. Hwang EC, Choi HS, Jung SI, et al. Use of the NMP22 BladderChek test in the diagnosis and follow-up of urothelial cancer: a cross-sectional study. *Urology*. 2011; 77(1):154-159.
9. Pajor G, Somogyi L, Meleg B, et al. Urovysion: Considerations on modifying current evaluation scheme, including immunophenotypic targeting and locally set, statistically derived diagnostic criteria. *Cytometry A*. 2011; 79(5):375-382.
10. Yerushalmi R, Tyldesley S, Kennecke H, et al. Tumor markers in metastatic breast cancer subtypes: frequency of elevation and correlation with outcome. *Ann Oncol*. 2011.
11. Fan B, Xiong B. Investigation of serum tumor markers in the diagnosis of gastric cancer. *Hepatogastroenterology*. 2011; 58(105):239-245.
12. Yamashita S, Tokuishi K, Hashimoto T, et al. Prognostic significance of HE4 expression in pulmonary adenocarcinoma. *Tumor Biol*. 2011; 32(2):265-271.
13. Van Gorp T, Cadron I, Despierre E, et al. HE4 and CA125 as a diagnostic test in ovarian cancer: prospective validation of the risk of ovarian malignancy algorithm. *Br Journal of Cancer*. 2011; 104(5):863-870.
14. Kim YM, Whang DH, Park J, et al. Evaluation of the accuracy of serum human epididymis protein 4 in combination with CA125 for detecting ovarian cancer: a prospective case-control study in a Korean population. *Clin Chem Lab Med*. 2011; 49(3):527-534.
15. Vezzosi D, Walter T, Laplanche A, et al. Chromogranin A measurement in metastatic well-differentiated gastroenteropancreatic neuroendocrine carcinoma: screening for false positives and a prospective follow-up study. *Int Journal of Biology Markers*. 2011.
16. Stokkel MP, Rietbergen DD, Korse CM, Taal BG. Somatostatin receptor scintigraphy and chromogranin A assay in staging and follow-up of patients with well-differentiated neuroendocrine tumors. *Nucl Med Commun*. 2011.

17. Yoo T, Lee WJ, Woo SM, et al. Pretreatment carbohydrate antigen 19-9 level indicates tumor response, early distant metastasis, overall survival, and therapeutic selection in localized and unresectable pancreatic cancer. *Int Journal Radiat Oncol Biol Phys*. 2011.
18. Molina R, Escudero JM, Augé JM, et al. HE4 a novel tumor marker for ovarian cancer: comparison with CA 125 and ROMA algorithm in patients with gynecological diseases. *Tumour Biol*. 2011 December; 32(6):1087–1095.
19. Gorp TV, Cadron I, Despierre E, et al. HE4 and CA125 as a diagnostic test in ovarian cancer: prospective validation of the Risk of Ovarian Malignancy Algorithm. *Br Journal of Cancer*. 2011 March 1; 104(5):863–870.
20. Shariat SF, Savage C, Chromecki TF et al. Assessing the clinical benefit of nuclear matrix protein 22 in the surveillance of patients with nonmuscle-invasive bladder cancer and negative cytology. *Cancer*. 2011; 117(13):2893-7.
21. MacDonald I, Murray A, Healey G, et al. Application of a High Throughput Method of Biomarker Discovery to Improvement of the EarlyCDT®-Lung Test. *PLoS One*. 2012; 7(12):e51002.
22. Chapman C, Healey G, Murray A, et al. EarlyCDT®-Lung test: improved clinical utility through additional autoantibody assays. *Tumour Biology*. 2012 October; 35(5):1319-1326.
23. Scowcroft H. Lung Screening - Still a need to caution, despite new blood test. *Cancer Research*. UK. March 2012.
24. Müller V, Riethdorf S, Rack B, et al. Prognostic impact of circulating tumor cells assessed with the CellSearch System™ and AdnaTest Breast™ in metastatic breast cancer patients: the DETECT study. *Breast Cancer Research*. 2012:(14)R118.
25. Daumerie C, Maiter D, and Gruson D. Serum calcitonin estimation in medullary thyroid cancer: basal or stimulated levels? *Thyroid Research*. 2013; 6(Suppl. 1):S4.
26. American Urological Association. Bladder Cancer Clinical Guideline. Chapter 1: The Management of Bladder Cancer: Diagnosis and Treatment Recommendations.
27. Carter HB, Albertsen PC, Barry MJ, et al. Early detection of prostate cancer. AUA Guideline. Issued April 2013.
28. NCCN Guidelines for Patients. National Comprehensive Cancer Network.
29. Ringel MD, Nabhan F. Approach to follow-up of the patient with differentiated thyroid cancer and positive anti-thyroglobulin antibodies. *Journal of Clinical Endocrinology Metab*. 2013; 98(8):3104-3110.
30. Kamat A, Dickstein R, Messetti F, et al. Use of fluorescence in situ hybridization to predict response to bacillus Calmette-Guerin therapy for bladder cancer: results of a prospective trial. *Journal of Urology*. 2012; 187(3):862-867.
31. Kamat A, Hegarty P, Gee J, et al. ICUD-EAU International consultation on bladder cancer 2012: Screening, diagnosis, and molecular markers. *European Urology*. 2013; 63:4-15.

32. Babacan A, Kizilaslan C, Gun I, et al. CA 125 and other tumor markers in uterine leiomyomas and their association with lesion characteristics. *International Journal of Clinical and Experimental Medicine*. 2014; 7(4):1078-1083.
33. Kaufman P, Bloom K, Burris H, et al. Assessing the discordance rate between local and central HER2 testing in women with locally determined HER2-negative breast cancer. *Cancer*. 2014 Jun 13.
34. The National Comprehensive Cancer Network (NCCN) task force report: Evaluating the clinical utility of tumor markers in oncology. *Journal of National Comprehensive Cancer Network*. 2011.
35. American Society of Clinical Oncology. Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Update. *Journal of Clinical Oncology*. November 2013; 31(13):3397-4013.
36. Agency for Healthcare Research and Quality (AHRQ). Multigene Panels in Prostate Cancer Risk Assessment. Evidence Reports/Technology Assessments, No. 209. 12-E020-EF. Rockville, MD: *Agency for Research and Quality*. July 2012.
37. Ip S, IJ D, Chung M ea. An evidence review of active surveillance in men with localized prostate cancer. Evidence report/Technology assessment no. 204 (Prepared by Tufts Evidence-based Practice Center under Contract No. HHSA 290-2007-10055-I). 2011; AHRQ Publication No.12-E003-EF, Rockville, MD: *Agency for Research and Quality*. October 21, 2014.
38. Klein E, Cooperberg M, Magi-Galluzzi C, et.al. A 17-gene Assay to Predict Prostate Cancer Aggressiveness in the Context of Gleason Grade Heterogeneity, Tumor Multifocality, and Biopsy Undersampling. *European Urology*. 2014; 550-560.
39. Knezevic D, Goddard A, Natraj N, et. al. Analytical Validation of the Oncotype DX Prostate Cancer Assay- A Clinical RT-PCR Assay Optimized for Prostate Needle Biopsies. *BMC Genomics*. 2013; 14:690.
40. NCCN Clinical Proactice Guidelines in Oncology: Prostate Cancer. Version 1.2015.
41. Allard WJ, Matera J, Miller MC, et al. Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases. *Clin Cancer Res*. 2004;10:6897-6904.
42. Cristofanilli M, Budd T, Ellis M, et al. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. *N Engl J Med*. 2004;351:781-791.
43. Harris L, Fritsche H, Mennel R, et al. American Society of Clinical Oncology 2007 Update of Recommendations for the Use of Tumor Markers in Breast Cancer. *J Clin Oncol*. 2007 Nov 20;25(33):5287-5312.
44. Food and Drug Administration. CellSearch™ Epithelial Cell Kit / CellSpotter™ Analyzer.
45. Harris LN, Ismaila N, McShane LM, et al. Use of biomarkers to guide decisions of adjuvant systemic therapy for women with early stage invasive breast cancer: American Society of Oncology Clinical Practice Guideline. *J Clin Oncol*. 2016 Feb(34).
46. NCCN Clinical Practice Guidelines in Oncology. Bladder Cancer. Version 1.2013.
47. Yoder BJ, Skacel M, Hedgepeth R, et al. Reflex UroVysion testing of bladder cancer

surveillance patients with equivocal or negative urine cytology: a prospective study with focus on the natural history of anticipatory positive findings. *Am J Clin Pathol*. 2007;127(2):295-301.

48. Hall MC, Chang SS, Dalbagni G, et al. Guideline for the management of nonmuscle invasive bladder cancer (stages Ta, T1, and Tis): 2007 update. (Reaffirmed 2010.) *J Urol*. 2007;178(6):2314-30.
49. Chen Y, Qu H, Jian M, et al. High level of serum AFP is an independent negative prognostic factor in gastric cancer. *Int J Biol Markers*. 2015; 30(4): e387-e393.
50. Bie Y and Zhang Z. Diagnostic value of serum HE4 in endometrial cancer: a meta-analysis. *World J Surg Oncol*. 2014; 1-6.
51. Geng B, Liang M, Ye X, Zhao W. Association of CA 15-3 and CEA with clinicopathological parameters in patients with metastatic breast cancer. *Molecular and Clinical Oncology*. 2015; 3(1): 232-236.
52. American Cancer Society. Tests for Prostate Cancer. May 15, 2017.
53. American Urological Association. PSA Testing for the Pre-treatment Staging and Post-treatment Management of Prostate Cancer. 2013.
54. American Urological Association. Clinically Localized Prostate Cancer: American Urological Association (AUA)/American Society for Radiation Oncology (ASTRO)/ Society of Urologic Oncology (SUO) Guideline. 2017.
55. National Cancer Institute. Tumor Markers. November 4, 2015.
56. The National Academy of Clinical Biochemistry. Use of Tumor Markers in Clinical Practice: Quality Requirements. Clinical Issues That Enhance The Reliability And Utility Of Tumor Markers. 2009. (AACC.org).
57. National Comprehensive Cancer Network. NCCN Guidelines for Patients. Prostate Cancer, Version 1.2016. 2016.